MedTrace Logo

A Phase II Study of Chiauranib in Combine With Capecitabine in TNBC

NCT05336721 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2025-03-24

No results posted yet for this study

Summary

This study is to evaluate the preliminary efficacy and safety of chiauranib in combine with capecitabine in advanced triple-negative breast cancer failed to prior anthracyclines and taxanes therapy

Conditions

  • Triple-negative Breast Cancer

Interventions

DRUG

Chiauranib

25mg/35mg/50mg orally once daily

DRUG

capecitabine

1000mg/m2 on Days 1-14 in a repeating 21-day cycle

Sponsors & Collaborators

  • Chipscreen Biosciences, Ltd.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-11-05
Primary Completion
2024-10-31
Completion
2024-11-05

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05336721 on ClinicalTrials.gov